What is Infervision?
Infervision leverages advanced artificial intelligence to revolutionize patient care within the healthcare sector. The company specializes in developing innovative solutions for hospitals and medical organizations, focusing on improving diagnostic accuracy and treatment efficacy. Its product suite includes sophisticated imaging systems like InferRead for diverse diagnostic applications and InferOperate for surgical planning and reconstruction. Infervision's primary clientele comprises radiologists, surgeons, researchers, and healthcare teams, all of whom benefit from solutions designed to optimize patient outcomes and streamline hospital operations. With a global footprint extending to over 25 countries and a robust portfolio of patents and publications, Infervision is dedicated to seamless integration into existing medical workflows.
How much funding has Infervision raised?
Infervision has raised a total of $165M across 3 funding rounds:
Series A
$8M
Series B
$18M
Series D
$139M
Series A (2017): $8M, investors not publicly disclosed
Series B (2017): $18M led by Genesis Capital, Qiming Venture Partners, and Sequoia Capital China
Series D (2021): $139M supported by CCB Trust, Goldman Sachs Group, and Z-Park Fund
Key Investors in Infervision
Genesis Capital
Genesis Capital is an independent investment and merchant banking firm focused on key growth sectors, providing tailored solutions for strategic growth initiatives and maximizing shareowner value through expertise in mergers, acquisitions, and private placements.
Qiming Venture Partners
Qiming Venture Partners is a venture capital firm that invests in early-stage and growth-stage companies in the technology and healthcare sectors.
Sequoia Capital China
Sequoia Capital China is a prominent venture capital firm known for its early and growth-stage investments in technology and healthcare companies, playing an active role in supporting entrepreneurs to build market-leading businesses.
What's next for Infervision?
The recent major enterprise-level funding, including the significant strategic investment, positions Infervision for accelerated expansion and further innovation in AI-powered medical technologies. This influx of capital is expected to fuel research and development, enhance product offerings, and broaden the company's market reach. Infervision's commitment to integrating advanced AI into healthcare workflows suggests a strategic focus on solidifying its role as a leader in medical imaging and surgical planning, potentially leading to new partnerships and advancements in patient care globally.
See full Infervision company page
